The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | CD19 CAR-T for CNS lymphoma
Tanya Siddiqi, MD, City of Hope, Duarte, CA, discusses an ongoing phase I trial (NCT02153580) investigating an autologous CD19-specific, hinge-optimized, CD28 costimulatory CAR-T product for the treatment of relapsed/refractory B-cell non-Hodgkin lymphomas (NHL), including CNS lymphoma. Thus far, early results appear promising in patients with primary and secondary CNS lymphoma – a group with great unmet clinical need. Expansion phase enrollment is continuing and the group also plan to explore an intraventricular route of CAR-T delivery. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
